IL154250A0 - Vaccination against host cell-associated herpesviruses - Google Patents

Vaccination against host cell-associated herpesviruses

Info

Publication number
IL154250A0
IL154250A0 IL15425001A IL15425001A IL154250A0 IL 154250 A0 IL154250 A0 IL 154250A0 IL 15425001 A IL15425001 A IL 15425001A IL 15425001 A IL15425001 A IL 15425001A IL 154250 A0 IL154250 A0 IL 154250A0
Authority
IL
Israel
Prior art keywords
host cell
vaccination against
herpesvirus
herpesviruses
against host
Prior art date
Application number
IL15425001A
Other languages
English (en)
Original Assignee
Lohmann Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Animal Health Gmbh filed Critical Lohmann Animal Health Gmbh
Publication of IL154250A0 publication Critical patent/IL154250A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15425001A 2000-08-03 2001-08-01 Vaccination against host cell-associated herpesviruses IL154250A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202757A EP1178111A1 (en) 2000-08-03 2000-08-03 Vaccination against host cell-associated herpesviruses
PCT/EP2001/008893 WO2002012288A2 (en) 2000-08-03 2001-08-01 Vaccination against host cell-associated herpesviruses

Publications (1)

Publication Number Publication Date
IL154250A0 true IL154250A0 (en) 2003-09-17

Family

ID=8171884

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15425001A IL154250A0 (en) 2000-08-03 2001-08-01 Vaccination against host cell-associated herpesviruses
IL154250A IL154250A (en) 2000-08-03 2003-02-02 Vaccine-linked surrogate-cellular vaccine for herpes viruses containing the genome @virley @recombinant

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154250A IL154250A (en) 2000-08-03 2003-02-02 Vaccine-linked surrogate-cellular vaccine for herpes viruses containing the genome @virley @recombinant

Country Status (24)

Country Link
US (1) US9073979B2 (ru)
EP (2) EP1178111A1 (ru)
JP (1) JP4313036B2 (ru)
KR (1) KR100633180B1 (ru)
CN (2) CN102151333A (ru)
AT (1) ATE412055T1 (ru)
AU (2) AU2001291716B2 (ru)
BR (1) BRPI0112989B1 (ru)
CA (1) CA2417923C (ru)
CZ (1) CZ303904B6 (ru)
DE (1) DE60136278D1 (ru)
EA (1) EA010721B1 (ru)
ES (1) ES2315306T3 (ru)
HR (1) HRP20030147B1 (ru)
HU (1) HU228262B1 (ru)
IL (2) IL154250A0 (ru)
MX (1) MXPA03001027A (ru)
NO (1) NO332621B1 (ru)
NZ (1) NZ524066A (ru)
PL (1) PL207958B1 (ru)
PT (1) PT1307565E (ru)
UA (1) UA84667C2 (ru)
WO (1) WO2002012288A2 (ru)
ZA (1) ZA200300842B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
WO2005085445A1 (ja) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University 組換え水痘帯状疱疹ウイルス
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US8809047B2 (en) 2009-12-21 2014-08-19 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
US9782474B2 (en) * 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
ES2700243T3 (es) * 2011-10-21 2019-02-14 Intervet Int Bv Construcciones del virus de la enfermedad de Marek recombinantes no patógenas que codifican antígenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad de Newcastle
EP2782597B1 (en) * 2011-11-23 2022-04-13 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN105597095A (zh) * 2015-12-30 2016-05-25 暨南大学 一种应用微载体培养Vero细胞制备基因缺失减毒疫苗的方法
CN105561303B (zh) * 2015-12-30 2019-04-05 暨南大学 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
CN105641692A (zh) * 2015-12-30 2016-06-08 暨南大学 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
US11174322B2 (en) * 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
BR112020012162A2 (pt) * 2017-12-20 2020-11-24 Intervet International B.V. diluente aprimorado para vacina contra alfa-herpesvírus associado à célula
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) * 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
GB8821441D0 (en) 1988-09-13 1988-10-12 Animal Health Inst Viral vectors
EP0486106A3 (en) 1990-11-16 1992-12-23 Akzo N.V. Marek's disease virus vaccine
AU657144B2 (en) * 1991-07-09 1995-03-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant Marek's disease virus, process for preparing the same and vaccine containing the same
JP3675569B2 (ja) 1995-04-28 2005-07-27 日本ゼオン株式会社 組み換えウイルス及びそれよりなるワクチン
KR19990028766A (ko) 1995-07-07 1999-04-15 나카노 가쓰히꼬 마렉 질환 바이러스 유전자 및 마렉 질환 예방용 백신에서그의 용도
US6306387B1 (en) * 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
AUPP684998A0 (en) * 1998-10-30 1998-11-26 Murdoch Institute for Research into Birth Defects Limited, The A method of recombination and agents useful for same
EP1038952A3 (en) 1998-12-09 2001-06-27 Pfizer Products Inc. Processes for preparation of Marek's Disease Virus using continuous avian cell lines
US6410222B1 (en) * 1998-12-14 2002-06-25 Juridical Foundation The Chemosero-Therapeutic Research Institute In ovo vaccination of marek's disease type I virus
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses

Also Published As

Publication number Publication date
ZA200300842B (en) 2004-04-30
EP1307565A2 (en) 2003-05-07
HUP0302664A2 (hu) 2003-11-28
AU2001291716B8 (en) 2002-02-18
MXPA03001027A (es) 2004-02-26
IL154250A (en) 2013-07-31
KR100633180B1 (ko) 2006-10-11
HUP0302664A3 (en) 2004-10-28
ES2315306T3 (es) 2009-04-01
NO20030524L (no) 2003-04-03
DE60136278D1 (de) 2008-12-04
ATE412055T1 (de) 2008-11-15
HU228262B1 (en) 2013-02-28
NO332621B1 (no) 2012-11-19
AU9171601A (en) 2002-02-18
US9073979B2 (en) 2015-07-07
EP1178111A1 (en) 2002-02-06
BRPI0112989B1 (pt) 2015-09-08
HRP20030147B1 (en) 2011-10-31
EA010721B1 (ru) 2008-10-30
HRP20030147A2 (en) 2005-04-30
NO20030524D0 (no) 2003-02-03
PL207958B1 (pl) 2011-02-28
WO2002012288A2 (en) 2002-02-14
CN102151333A (zh) 2011-08-17
EA200300215A1 (ru) 2003-08-28
CA2417923C (en) 2010-06-29
JP4313036B2 (ja) 2009-08-12
PT1307565E (pt) 2009-01-28
EP1307565B1 (en) 2008-10-22
CN1503843A (zh) 2004-06-09
CA2417923A1 (en) 2002-02-14
JP2004505993A (ja) 2004-02-26
CZ2003324A3 (cs) 2003-06-18
BR0112989A (pt) 2003-09-09
NZ524066A (en) 2004-11-26
KR20030036657A (ko) 2003-05-09
CZ303904B6 (cs) 2013-06-19
US20030165537A1 (en) 2003-09-04
UA84667C2 (ru) 2008-11-25
AU2001291716B2 (en) 2007-06-07
PL365190A1 (en) 2004-12-27
WO2002012288A3 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
IL154250A0 (en) Vaccination against host cell-associated herpesviruses
Mettenleiter Molecular biology of pseudorabies (Aujeszky's disease) virus
EP1298139A3 (en) Avian herpes virus-based recombinant infectious bursal disease vaccine
AU585126B2 (en) Recombinant herpes simplex viruses, vaccines and methods
CA2166367A1 (en) Live recombinant avian vaccine using an avian herpesvirus as vector
WO1990002803A3 (en) Viral vaccines
NZ228409A (en) Marek's disease virus used as a multifunctional live vaccine
CA2116355A1 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
DK0606452T3 (da) Vektorvacciner fra rekombinant katteherpesvirus
Nagesha et al. Analysis of the nucleotide sequence of five genes at the left end of the unique short region of the equine herpesvirus 4 genome
ATE317439T1 (de) Virale vakzine
EA200100720A1 (ru) Вирусная вакцина на основе делеционного вируса герпеса крупного рогатого скота типа 1 (bhv-1)
Johnson et al. Nucleotide sequence of the left-terminus of infectious laryngotracheitis virus (Gallid herpesvirus 1) SA-2 strain
HUP0002374A2 (hu) Egy diszfunkcionális 71 gén régiót tartalmazó rekombináns 1-es típusú ló herpeszvírus (EHV-1) és alkalmazása vakcinaként
Becker Live Herpesvirus Vaccines: Serendipity or Engineering of the Virus Genome
Junker UL 54. 5 of Marek's disease virus(MDV)